Evidence map›Paper›PMID 40866422›Full record

ArticleScientific reports2025

Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivo.

Gavin Lewis, Nelson L S Chan, Brendon Frank, Larisa A Troitskaya, Brian Law, Ursula Edman, Marina E Fomin, Steven J Chapin, Juha Punnonen, Daniel J Capon

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Gavin LewisHinge Bio, Inc., Burlingame, CA, 94010, USA.
Nelson L S ChanHinge Bio, Inc., Burlingame, CA, 94010, USA.
Brendon FrankHinge Bio, Inc., Burlingame, CA, 94010, USA.
Larisa A TroitskayaHinge Bio, Inc., Burlingame, CA, 94010, USA.
Brian LawHinge Bio, Inc., Burlingame, CA, 94010, USA.
Ursula EdmanHinge Bio, Inc., Burlingame, CA, 94010, USA.
Marina E FominHinge Bio, Inc., Burlingame, CA, 94010, USA.
Steven J ChapinHinge Bio, Inc., Burlingame, CA, 94010, USA.
Juha PunnonenHinge Bio, Inc., Burlingame, CA, 94010, USA. juha.punnonen@hingebio.com.
Daniel J CaponHinge Bio, Inc., Burlingame, CA, 94010, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent clinical studies suggest that more potent B cell depleting therapies and targeting more than one B cell antigen may result in improved clinical responses in autoimmune diseases and hematological malignancies. Here we describe an anti-CD19/CD20 bispecific antibody, HB2198, generated using GEM-DIMER™ technology. HB2198 incorporates Fab domains from rituximab and humanized FMC63 (huFMC63) for bivalent binding of both CD19 and CD20 and comprises two enhanced Fc domains to enable powerful effector functions via bivalent binding of Fcγ receptors (FcγR). Enhanced bivalent binding of HB2198 to FcγR was confirmed in vitro. HB2198 demonstrated robust depletion of human B cells that exceeded the levels observed with comparator anti-CD19 or anti-CD20 IgG1 antibodies in vitro. The mechanism of action of HB2198 included enhanced antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as well as complement-dependent cytotoxicity (CDC) and direct cell killing activity. In cynomolgus monkeys, HB2198 administration resulted in > 99% depletion of circulating B cells within 1-3 days and mediated a durable shift in proportions of naïve and memory B cells in vivo. These data support the conclusion that HB2198 may provide an improved treatment option when potent and broad depletion of both CD19

Indexed as

Antibodies, BispecificAntigens, CD19Antigens, CD20B-LymphocytesImmunoglobulin Fc FragmentsMemory B CellsAnimalsAntibody-Dependent Cell CytotoxicityHumansLymphocyte DepletionMacaca fascicularisPhagocytosisReceptors, IgGRituximabAntibodies, BispecificAntigens, CD19Antigens, CD20Immunoglobulin Fc FragmentsReceptors, IgGRituximabAutoimmune therapyB cell depletionMemory B cellsSLE

Identifiers

PMID40866422
PMCPMC12391342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.